Society of Hematologic Oncology
LightNews LightNews
banner
societyofhemonc.bsky.social
Society of Hematologic Oncology
@societyofhemonc.bsky.social
43 followers 22 following 240 posts
Get the latest news on sohoinsider.com, the official news source from SOHO.

Register for SBBC soho.click/SBBC
Become a member for free at soho.click/join.
Posts Replies Media Videos
societyofhemonc.bsky.social
Watch our roundtable discussion on CELLMods in LBCL & follicular lymphoma.

sohoinsider.com/roundtable-d...
December 19, 2025 at 9:49 PM
societyofhemonc.bsky.social
Whether you became a SOHO member this year or in 2012, our very first year, we thank you for being part of our society! Membership to SOHO is free and offers many benefits. soho.click/join
December 18, 2025 at 8:58 PM
societyofhemonc.bsky.social
“It’s really exciting to see menin inhibitors moving to frontline AML… we’re already seeing much higher response rates," Dr. Lore Gruenbaum says in this video interview from #ASH2025
buff.ly/x51gcxb
December 18, 2025 at 2:20 AM
societyofhemonc.bsky.social
Updated phase 3 VERIFY results confirm rusfertide significantly improves PV outcomes over SOC

sohoinsider.com/meetings-con...
Updated phase 3 VERIFY results confirm rusfertide improves PV
Rusfertide, which has received Breakthrough Therapy Designation, Orphan Drug Designation and Fast Track Designation from the FDA.
sohoinsider.com
December 16, 2025 at 9:43 PM
societyofhemonc.bsky.social
SOHO Insider announces new Community Oncology Brown Bag Series

sohoinsider.com/news/soho-in...
SOHO Community Oncology Brown Bag Series - SOHO Insider
SOHO Insider launches Virtual Community Oncology Brown Bag Series, an informal lunchtime sessions with community oncologists.
sohoinsider.com
December 16, 2025 at 1:42 AM
societyofhemonc.bsky.social
‘Promising’ early-phase results seen with KLN-1010, an off-the-shelf in vivo CAR-T for myeloma

sohoinsider.com/news/promisi...
KLN-1010 Promising Early In Vivo CAR-T for Myeloma - SOHO Insider
Phase 1 inMMyCAR trial shows KLN-1010 promising clinical activity with manageable toxicity in multiple myeloma
sohoinsider.com
December 14, 2025 at 6:10 PM
societyofhemonc.bsky.social
ICYMI: US FDA approves liso-cel in relapsed or refractory MZL

sohoinsider.com/news/us-fda-...
US FDA approves liso-cel in relapsed or refractory MZL
The US Food and Drug Administration has approved lisocabtagene maraleucel (liso-cel; Breyanzi), a CD19-directed CAR T-cell therapy, for adult patients with relapsed or refractory marginal zone…
sohoinsider.com
December 13, 2025 at 5:45 PM
societyofhemonc.bsky.social
Epcoritamab + rituximab + lenalidomide may become the new standard for second-line follicular lymphoma. #ASH25

sohoinsider.com/lymphoma/epc...
Epcoritamab triplet may set new standard in 2L follicular lymphoma
Epcoritamab in combination with rituximab and lenalidomide has the potential to be the new standard of care in patients with second-line follicular lymphoma, according to results from the phase 3…
sohoinsider.com
December 13, 2025 at 4:52 PM
societyofhemonc.bsky.social
Phase 3 study finds fixed-duration treatment non-inferior to continuous treatment in CLL

sohoinsider.com/news/phase-3...
Phase 3 CLL17: Fixed-Duration Non-Inferior in CLL - SOHO Insider
Phase 3 CLL17 trial: Fixed-duration targeted therapy non-inferior to continuous treatment in untreated CLL, ASH 2025.
sohoinsider.com
December 8, 2025 at 12:04 PM
societyofhemonc.bsky.social
Extended MorningSun study results show ‘promising’ survival with subcutaneous mosunetuzumab #ASH25

sohoinsider.com/news/extende...
Phase 2 MorningSun study - SOHO Insider
Phase 2 MorningSun update: 91.9% OS in untreated high-burden FL with SC mosunetuzumab + optional maintenance.
sohoinsider.com
December 6, 2025 at 9:03 PM
societyofhemonc.bsky.social
1st SOHO Asia meeting will be held in Tapei in January 2026. Register now; the meeting will be held Jan. 23-25.

sohoinsider.com/news/1st-soh...
1st SOHO Asia to be held in January 2026 - SOHO Insider
Join us at SOHO Asia 2026 – the premier meeting advancing treatment of hematologic malignancies across Asia and beyond.
sohoinsider.com
December 6, 2025 at 3:44 AM
societyofhemonc.bsky.social
Phase 1 study of menin inhibitor terminated early due to lack of response, differentiation syndrome

sohoinsider.com/news/phase-1...
DS-1594b phase 1 stopped: poor efficacy, differentiation syndrome - SOHO Insider
Menin inhibitor DS-1594b trial stopped early: poor efficacy and differentiation syndrome in nearly a third of patients.
sohoinsider.com
December 3, 2025 at 4:36 PM
societyofhemonc.bsky.social
Extramedullary disease in MM associated with severe toxicities following BCMA-targeted CAR T-cell therapy

sohoinsider.com/news/extrame...
Extramedullary MM linked to severe toxicities after BCMA CAR-T - SOHO Insider
Extramedullary disease in multiple myeloma linked to higher severe toxicities after BCMA-targeted CAR-T therapy.
sohoinsider.com
December 2, 2025 at 11:56 PM
societyofhemonc.bsky.social
Visit us at the SOHO Booth 1813 during #ASH2025 to learn about our FREE membership and all the programs we have to offer.
December 2, 2025 at 2:24 AM
societyofhemonc.bsky.social
“Bispecifics are like a matchmaker… if it’s a perfect match, fireworks happen!” Dr. Graff said. Listen to our new podcast episode here: sohoinsider.com/lymphoma/tar...
November 30, 2025 at 6:48 PM
societyofhemonc.bsky.social
2027-2028 SOHO President-elect Valeria Santini, MD, grew up in Florence, where she says the city’s beauty, history, and art shaped her entire outlook on life.

Read our interview with her:

sohoinsider.com/news/pathway...
Pathways & Perspectives with Valeria Santini, MD
Pathways & Perspectives with Valeria Santini, MD, where she discuss MDS, leukemia, and growing up in Florence.
sohoinsider.com
November 26, 2025 at 4:02 AM
societyofhemonc.bsky.social
Liso-cel receives expanded approval in R/R MCL by European Commission
sohoinsider.com/lymphoma/lis...
Lisocabtagene maraleucel receives expanded approval by EC
Lisocabtagene maraleucel receives expanded approval by European Commission in relapsed or refractory mantle cell lymphoma, according to BMS.
sohoinsider.com
November 25, 2025 at 1:53 AM
societyofhemonc.bsky.social
Dr. Al-Ola A Abdallah discusses the DREAMM-7 study in this video interview:

sohoinsider.com/video-interv...
November 24, 2025 at 3:56 AM
societyofhemonc.bsky.social
One of the takeaways from Dr. Selina Luger's
SBBC morning session is that #ALL has had many treatments advancements but there are still toxicity challenges.

sohoinsider.com/news/selina-...
Safer, more effective ALL therapies still needed
Even with these treatment advances in ALL, relapse and treatment-related toxicities remain major challenges, according to Dr. Luger.
sohoinsider.com
November 20, 2025 at 6:50 PM
societyofhemonc.bsky.social
Ahead of SBBC, SOHO Insider asked Dr. Vose for her take on the biggest lymphoma developments of 2025. SBBC starts tomorrow. Register today at soho.click/SBBC. SOHO members: it is FREE. Become a SOHO member for free at soho.click/join.

sohoinsider.com/lymphoma/a-2...
November 20, 2025 at 1:16 AM
societyofhemonc.bsky.social
FDA approves epcoritamab combo in R/R follicular lymphoma

sohoinsider.com/news/fda-app...
US FDA approves epcoritamab combo in R/R follicular lymphoma
The FDA approved epcoritamab in combination with rituximab, lenalidomide for adult patients with relapsed or refractory follicular lymphoma.
sohoinsider.com
November 19, 2025 at 8:18 PM
societyofhemonc.bsky.social
Does the future of myeloma treatment belong to trispecific antibodies?

sohoinsider.com/multiple-mye...
November 19, 2025 at 2:50 AM
societyofhemonc.bsky.social
Tafasitamab gets positive CHMP opinion in R/R follicular lymphoma

sohoinsider.com/lymphoma/taf...
Tafasitamab gets positive CHMP opinion in R/R follicular lymphoma
Tafasitamab gets positive CHMP opinion in R/R follicular lymphoma. The opinion is based on results from the phase 3 inMIND trial.
sohoinsider.com
November 17, 2025 at 7:49 PM
societyofhemonc.bsky.social
FDA approves ziftomenib for relapsed or refractory NMP1-mutated AML
sohoinsider.com/meetings-con...
FDA approves ziftomenib for R/R NMP1-mutated AML
The US Food and Drug Administration has approved the menin inhibitor ziftomenib for treatment of relapsed or refractory NMP1-mutated acute myeloid leukemia in adult patients who have no alternative tr...
sohoinsider.com
November 15, 2025 at 1:55 AM
societyofhemonc.bsky.social
"We ... started these studies in the older patients because we were anxious about treating younger patients with chemotherapy-free regimens,"
Dr. Short says in this discussion with Dr. Hagop Kantarjian.

Watch the video:

sohoinsider.com/news/drs-kan...
November 14, 2025 at 4:42 AM